Hydrogen inhalation in rehabilitation program of the medical staff recovered from COVID-19
Active hydrogen inhalation (H(H2O)m) has powerful antioxidant and antiapoptotic effects. In recent years, it has been used in a number of experimental and clinical studies.Aim. To study the safety and effectiveness of inhalation of the “active form of hydrogen” (AFV;(H(H2O)m)) in the rehabilitation program of coronavirus disease 2019 (COVID-19) survivors during the recovery period.Material and methods. This randomized controlled parallel prospective study included 60 COVID-19 survivors with post-COVID-19 syndrome (ICD-10: U09.9) during the recovery period, with clinical manifestations of chronic fatigue syndrome (CFS), who received standard therapy in accordance with the management protocol of patients with CFS (ICD-10: G93.3): physiotherapy and medication therapy with drugs containing magnesium, B vitamins and L-carnitine. The patients were divided into 2 groups. The experimental group (n=30) included patients who received hydrogen inhalation for 90 minutes every day during 10 days (SUISONIA hydrogen inhalation device, Japan). The control group (n=30) consisted of patients who received standard therapy. In both groups, patients were comparable in sex and mean age: in the experimental group — 53 (22; 70) years, in the control group — 51 (25; 70) years. Biological markers of systemic inflammation, oxygen transport, lactate metabolism, intrapulmonary shunting, 6-minute walk test, and vascular endothelial function were determined in all patients on the 1st and 10th days of follow-up.Results. In the experimental group, a decrease in following parameters was revealed: stiffness index (SI), from 8,8±1,8 to 6,8±1,5 (p<0,0001); ALT, from 24,0±12,7 to 20,22±10,61 U/L (p<0,001); venous blood lactate, from 2,5±0,8 to 1,5±1,0 mmol/L (p<0,001); capillary blood lactate, from 2,9±0,8 to 2,0±0,8 mmol/L (p<0,0001); estimated pulmonary shunt fraction (Qs/Qt, Berggren equation, 1942) from 8,98±5,7 to 5,34±3,2 (p<0,01); white blood cells, from 6,64±1,57 to 5,92±1,32 109/L. In addition, we revealed an increase in the refractive index (RI) from 46,67±13,26% to 63,32±13,44% (p<0,0001), minimum blood oxygen saturation (SpO2) from 92,25±2,9 to 94,25±1, 56% (p<0,05), direct bilirubin from 2,99±1,41 to 3,39±1,34 pmol/L (p<0,01), partial oxygen tension (PvO2) from 26,9±5,0 to 34,8±5,6 mm Hg (p<0,0001), venous oxygen saturation (SvO2) from 51,8±020,6 to 61,1±018,1% (p<0,05), partial capillary oxygen tension (PcO2) from 48,7±15,4 to 63,8±21,2 mm Hg (p<0,01), capillary oxygen saturation (ScO2) from 82,2±4,2 to 86,2±4,8% (p<0,01), distance in 6 minute walk test from 429±45,0 to 569±60 m.Conclusion. Inhalation therapy with H(H2O)m in the rehabilitation program of COVID-19 survivors during the recovery period is a safe and highly effective method. Manifestations of silent hypoxemia and endothelial dysfunction decreased, while exercise tolerance increased. As for laboratory tests, a decrease in the white blood cell count, estimated pulmonary shunt fraction and lactate content parameters was revealed..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Кардиоваскулярная терапия и профилактика - 20(2021), 6 |
| Sprache: |
Russisch |
|---|
| Beteiligte Personen: |
L. V. Shogenova [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
активная форма водорода (h(h2o)m) |
|---|
| doi: |
10.15829/1728-8800-2021-2986 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ029327725 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ029327725 | ||
| 003 | DE-627 | ||
| 005 | 20230503021217.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2021 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.15829/1728-8800-2021-2986 |2 doi | |
| 035 | |a (DE-627)DOAJ029327725 | ||
| 035 | |a (DE-599)DOAJ4d32b81b25b44bfab0e7b374a7b08d65 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 050 | 0 | |a RC666-701 | |
| 100 | 0 | |a L. V. Shogenova |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hydrogen inhalation in rehabilitation program of the medical staff recovered from COVID-19 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Active hydrogen inhalation (H(H2O)m) has powerful antioxidant and antiapoptotic effects. In recent years, it has been used in a number of experimental and clinical studies.Aim. To study the safety and effectiveness of inhalation of the “active form of hydrogen” (AFV;(H(H2O)m)) in the rehabilitation program of coronavirus disease 2019 (COVID-19) survivors during the recovery period.Material and methods. This randomized controlled parallel prospective study included 60 COVID-19 survivors with post-COVID-19 syndrome (ICD-10: U09.9) during the recovery period, with clinical manifestations of chronic fatigue syndrome (CFS), who received standard therapy in accordance with the management protocol of patients with CFS (ICD-10: G93.3): physiotherapy and medication therapy with drugs containing magnesium, B vitamins and L-carnitine. The patients were divided into 2 groups. The experimental group (n=30) included patients who received hydrogen inhalation for 90 minutes every day during 10 days (SUISONIA hydrogen inhalation device, Japan). The control group (n=30) consisted of patients who received standard therapy. In both groups, patients were comparable in sex and mean age: in the experimental group — 53 (22; 70) years, in the control group — 51 (25; 70) years. Biological markers of systemic inflammation, oxygen transport, lactate metabolism, intrapulmonary shunting, 6-minute walk test, and vascular endothelial function were determined in all patients on the 1st and 10th days of follow-up.Results. In the experimental group, a decrease in following parameters was revealed: stiffness index (SI), from 8,8±1,8 to 6,8±1,5 (p<0,0001); ALT, from 24,0±12,7 to 20,22±10,61 U/L (p<0,001); venous blood lactate, from 2,5±0,8 to 1,5±1,0 mmol/L (p<0,001); capillary blood lactate, from 2,9±0,8 to 2,0±0,8 mmol/L (p<0,0001); estimated pulmonary shunt fraction (Qs/Qt, Berggren equation, 1942) from 8,98±5,7 to 5,34±3,2 (p<0,01); white blood cells, from 6,64±1,57 to 5,92±1,32 109/L. In addition, we revealed an increase in the refractive index (RI) from 46,67±13,26% to 63,32±13,44% (p<0,0001), minimum blood oxygen saturation (SpO2) from 92,25±2,9 to 94,25±1, 56% (p<0,05), direct bilirubin from 2,99±1,41 to 3,39±1,34 pmol/L (p<0,01), partial oxygen tension (PvO2) from 26,9±5,0 to 34,8±5,6 mm Hg (p<0,0001), venous oxygen saturation (SvO2) from 51,8±020,6 to 61,1±018,1% (p<0,05), partial capillary oxygen tension (PcO2) from 48,7±15,4 to 63,8±21,2 mm Hg (p<0,01), capillary oxygen saturation (ScO2) from 82,2±4,2 to 86,2±4,8% (p<0,01), distance in 6 minute walk test from 429±45,0 to 569±60 m.Conclusion. Inhalation therapy with H(H2O)m in the rehabilitation program of COVID-19 survivors during the recovery period is a safe and highly effective method. Manifestations of silent hypoxemia and endothelial dysfunction decreased, while exercise tolerance increased. As for laboratory tests, a decrease in the white blood cell count, estimated pulmonary shunt fraction and lactate content parameters was revealed. | ||
| 650 | 4 | |a водород | |
| 650 | 4 | |a активная форма водорода (h(h2o)m) | |
| 650 | 4 | |a covid-19 | |
| 650 | 4 | |a постковидный синдром | |
| 650 | 4 | |a реабилитация | |
| 650 | 4 | |a лактат | |
| 650 | 4 | |a транспорт кислорода | |
| 650 | 4 | |a скрытая гипоксемия | |
| 653 | 0 | |a Diseases of the circulatory (Cardiovascular) system | |
| 700 | 0 | |a Thi Tuet Truong |e verfasserin |4 aut | |
| 700 | 0 | |a N. O. Kryukova |e verfasserin |4 aut | |
| 700 | 0 | |a K. A. Yusupkhodzhaeva |e verfasserin |4 aut | |
| 700 | 0 | |a D. D. Pozdnyakova |e verfasserin |4 aut | |
| 700 | 0 | |a T. G. Kim |e verfasserin |4 aut | |
| 700 | 0 | |a A. V. Chernyak |e verfasserin |4 aut | |
| 700 | 0 | |a Е. N. Kalmanova |e verfasserin |4 aut | |
| 700 | 0 | |a O. S. Medvedev |e verfasserin |4 aut | |
| 700 | 0 | |a T. A. Kuropatkina |e verfasserin |4 aut | |
| 700 | 0 | |a S. D. Varfolomeev |e verfasserin |4 aut | |
| 700 | 0 | |a A. M. Ryabokon |e verfasserin |4 aut | |
| 700 | 0 | |a O. А. Svitich |e verfasserin |4 aut | |
| 700 | 0 | |a M. P. Kostinov |e verfasserin |4 aut | |
| 700 | 0 | |a Ibaraki Kunio |e verfasserin |4 aut | |
| 700 | 0 | |a Maehara Hiroki |e verfasserin |4 aut | |
| 700 | 0 | |a A. G. Chuchalin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Кардиоваскулярная терапия и профилактика |d «SILICEA-POLIGRAF» LLC, 2019 |g 20(2021), 6 |w (DE-627)DOAJ000143863 |x 26190125 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2021 |g number:6 |
| 856 | 4 | 0 | |u https://doi.org/10.15829/1728-8800-2021-2986 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/4d32b81b25b44bfab0e7b374a7b08d65 |z kostenfrei |
| 856 | 4 | 0 | |u https://cardiovascular.elpub.ru/jour/article/view/2986 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1728-8800 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2619-0125 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2021 |e 6 | ||